Clovis spikes ovarian cancer combo after 'underwhelming' efficacy; Servier wins priority review for Tibsovo expansion
Clovis Oncology updated investors with its first quarter results on Wednesday morning, and among its revelations proved some troubling news for a Bristol Myers Squibb …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.